Mary DiBiase - Oct 4, 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
Chief Operating Officer
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Stock symbol
XFOR
Transactions as of
Oct 4, 2024
Transactions value $
-$38,329
Form type
4
Date filed
10/8/2024, 04:44 PM
Previous filing
Sep 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Award $0 +231K +79.78% $0.00 520K Oct 4, 2024 Direct F1
transaction XFOR Common Stock Sale -$38.3K -67.7K -13.02% $0.57 452K Oct 7, 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition.
F2 These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.55 to $0.6043, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.